Editöre Mektup
BibTex RIS Kaynak Göster

YOĞUN BAKIMA YATAN HASTALARDA ATIII SEVİYESİ VE PROGNOSTİK DEĞERİ

Yıl 2010, Cilt: 1 Sayı: 1, 1 - 5, 03.03.2015

Öz

Amaç: Antitrombin 3’ün yo÷un bakıma yatan hastalardaki prognostik de÷erini araútırmak.
Gereç ve yöntem: Çalıúmamızda yo÷un bakıma yatan 215 hasta dahil edildi. Hastalar 1-16 yaú arasındaydı, 90’ı kız 125’i erkekti.
Bulgular: Antitrombin III aktivitesindeki azalma prognozla yakın iliúkili görülmektedir.
Sonuç: Bizim çalıúmamızda vardı÷ımız sonuç gibi Antitrombin III aktivitesindeki azalma prognozla yakın iliúkili görülmektedir.
Özellikle aktivitenin %50 nin altına inmesi güçlü bir prognostik gösterge olarak kabul edilmektedir.  

Kaynakça

  • Schnitzel H, Weilemann L S. Antithrombin substitution therapy. Blood Coag Fibrinol 1998; 9 (suppl 3): 17-22.
  • Pratt CW, Church FC. Antithrombin structure and function. Semin Hematol 1991; 28: 3-9.
  • Van’t Veer C, Mann KG. Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor,
  • antithrombin III and heparin cofactor II. J Biol Chem 1997; 14: 4367-4377.
  • Pizzo SV, Durham Ph D. Serpin receptor 1: hepatic receptor that mediates the clearance of antithrombin III-proteinase complexes. Am J Med
  • ; 87 (suppl 3B): 10-14.
  • Mammen EF. Antithrombin :Its physiological importance and role in D
  • Eisele B, Lamy M. Clinical experience with antithrombin III concentrates in critically ill patients with sepsis and multiple organ failure. Semin
  • Thromb Hemost 1998; 24(1):71-80.
  • Nielsen JD. The effect of antithrombin on systemic inflammatory response in disseminated intravascular coagulation. Blood Coag Fibrinol 1998;
  • (suppl 3): 11-15.
  • Davie E, Ratnoff O D. Waterfall sequence for intrinsic blood clotting. Science 1964; 145: 1310-1312.
  • Vinazzer H. Clinical use’s of ATIII. Von Sang 1987; 53: 193-198.
  • Mamnen EF. Antithrombin: Its physiological importance and role in DIC. Semin Thromb Hemost 1998; 24: 19-25.
  • Tahtacı N, Elmacıo
  • Niessen RWL, Lamping RJ, Jonsen PM, et. al. Antithrombin acts as a negative acute phase protein as established with studies on Hep G2 cells
  • and in baboons. Thromb Haemost 1997; 78:1088-1092.
  • Mammen EF, Balk R, Emerson T Jr, et. al. Therapeutic use of antithrombin concentrates in sepsis. Semin Thromb Hemost 1998; 24: 183-194.
  • Dickneite G. Antithrombin III in animal models of sepsis and organ failure. Semin Thromb Hemost 1998; 24: 61-69.
  • Warren BL, Eid A, Singer P, et. al. High dose antithrombin III in severe sepsis. A randomized controlled trial. JAMA 2001; 286: 1869-1878.
  • Olcay L, Gürgey A. Herediter trombotik hastalıklar. Katkı Pediatri Derg 1995; 6:887-907.
  • Casgriff JM, Bishop DT, Hersfold EJ, Skolnick MH, et. al. Hereditary antithrombin deficiency diagnosis and treatment. Medicine 1983; 62: 4.
  • Wilson C, Walker ID, Davidson JF. Mesenteric venous thrombosis and ATIII deficiency. J Clin Pathol 1987; 40: 906-908.
  • Lee MK. Cerebral Venous Thrombosis with ATIII deficiency. Aust NZ J Med 1991;21.
  • Levi M, Ten Cate H, Van der Poll T, Van Deventer SJH. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993; 270: 975-
  • -
  • Vervloet MG, Thijs LG, Hack CE. Derangement’s of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin Thromb
  • Hemostas 1998; 24: 33-44.
  • Mesters RM, Mannucci PM, Coppola R, Keller T, Ostermann H, Kienast J. Factor VIIa and antithrombin III activity during severe sepsis and septic
  • shock in neutropenic patients. Blood 1996; 88: 881-886.
  • Hellgren M, Javelin L, Hagnevik K, et. al. Antithrombin III concentrate as adjuvant in DIC treatment- a pilot study in 9 severely ill patients. Thromb
  • Res 1984; 36:459-466.
  • Blauhut B, Kramar H, Vinazzer H, et. al. Substitution of antithrombin III in shock and DIC: A randomised study. Thromb Res 1985; 29:81-89.
  • Montgomery RR, Scott JP. Hemorrhagic and thrombotic disease. Behrman Nelson Texbook Pediatrics 17th edition 2004; 1651-1656.
  • Nesheim ME. A simple rate low that describes the kinetics of the heparin catalysed reaction between antithrombin III and trombin. J Biol Chem
  • ; 23(14): 708.
  • Van der Poll T, van Deventer SJH. Cytokines and anticytokines in the pathogenesis of sepsis. Infect Dis Clin North Am 1999; 13: 413-426.
  • Bone RC. Modulators of coagulation. A critical appraisal of their role in sepsis. Arch Intern Med 1992; 152: 1381-1389.
  • Bone RC. Sepsis and coagulation. Ann Important Link. Chest 1992; 101 (3): 594-595.
  • Heyderman RS. Sepsis and intravascular thrombosis. Arch Dis Child 1993; 68: 621-625.
  • Fourrier F, Chopin C, Goudemand J, Hendryx S, Caron C, Rime A, et. al. Septic shock, multiple organ failure and disseminated intravascular
  • coagulation. Compared patterns of antithrombin III, protein C and protein S deficiencies. Chest 1992; 101: 816-823.
  • Mammen EF. The haematological manifestations of sepsis. J Antimicrob Chemother 1998; 41 (Suppl A): 17-24.
  • Levi M, ten Cate H, Disseminated intravascular coagulation. N Engl J Med 1999; 341: 586-592.
  • Bick RL. Disseminated intravascular coagulation: pathophysiological mechanisms and manifestations. Semin Thromb Hemostas 1998; 24: 3-18.
  • Blanco A, Guisasola JA, Solis P, Bachiller R, Gonzalez H. Fibronectin in meningococcal sepsis. Correlation with antithrombin III and protein C.
  • Acta Pediatr Scand 1990; 79: 73-76.
  • Fourrier F, Lestavel P, Chopin C, Marey A, Goudemand J, Rime A, et. al. Meningococcemia and purpura fulminans in adults: acute deficiencies of
  • protein C and protein S and early treatment with antithrombin III concentrates. Intensive Care Med 1990; 16: 121-124.
  • Sanchez MA, at al. Abnormalities in coagulation and fibrinolysis in septic shock with purpura. An Esp Pediatr 2002; 56(2): 99-103.
  • Dschietzig T, et.al. Stimulation of pulmonary big endothelin-1 and endothelin-1 by antithrombin III: a rationale for combined application of
  • antithrombin III and endothelin antagonist in sepsis-related acute respiratory distres syndrome? Crit Care Med. 2000 Jul; 28(7): 2445-9.
  • Uchiba M, Okajima K. Antithrombin III prevents LPS-induced vascular injury: Novel biological activity of ATIII. Thromb Haemostas 1997; 23: 583-
  • -
  • Sundar S, Mall RK, Dube B, Singh VP. Antithrombin III in liver disorders. J Assoc Physicians India. 1991; 39(7): 522-4.
  • Pettila V, Pentti J, Pettila M, Takkunen O, Jousela I. Predictive value of antithrombin III and serum C-reactive protein concentration in critically ill
  • patients with suspected sepsis. Crit Care Med 2002; 30(2): 271-5.

AT-III LEVEL AND ITS PROGNOSTIC SIGNIFICANCE IN PATIENTS IN PEDIATRIC INTENSIVE CARE UNIT

Yıl 2010, Cilt: 1 Sayı: 1, 1 - 5, 03.03.2015

Öz

Aim: Our objective is to investigate the prognostic value of Antithrombin III in our intensive care.
Gereç ve yöntem: 215 patients admitted to intensive care were included. The age of patients were between 1-16 years, 125 were
male, and 90 female.
Results: Prognosis is related to the decrease in antithrombin III activity.
Conclusion: Our study showed that the decrease in antithrombin III activity is closely related to prognosis. Particular activity to
below 50% is considered a powerful prognostic indicator. 

Kaynakça

  • Schnitzel H, Weilemann L S. Antithrombin substitution therapy. Blood Coag Fibrinol 1998; 9 (suppl 3): 17-22.
  • Pratt CW, Church FC. Antithrombin structure and function. Semin Hematol 1991; 28: 3-9.
  • Van’t Veer C, Mann KG. Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor,
  • antithrombin III and heparin cofactor II. J Biol Chem 1997; 14: 4367-4377.
  • Pizzo SV, Durham Ph D. Serpin receptor 1: hepatic receptor that mediates the clearance of antithrombin III-proteinase complexes. Am J Med
  • ; 87 (suppl 3B): 10-14.
  • Mammen EF. Antithrombin :Its physiological importance and role in D
  • Eisele B, Lamy M. Clinical experience with antithrombin III concentrates in critically ill patients with sepsis and multiple organ failure. Semin
  • Thromb Hemost 1998; 24(1):71-80.
  • Nielsen JD. The effect of antithrombin on systemic inflammatory response in disseminated intravascular coagulation. Blood Coag Fibrinol 1998;
  • (suppl 3): 11-15.
  • Davie E, Ratnoff O D. Waterfall sequence for intrinsic blood clotting. Science 1964; 145: 1310-1312.
  • Vinazzer H. Clinical use’s of ATIII. Von Sang 1987; 53: 193-198.
  • Mamnen EF. Antithrombin: Its physiological importance and role in DIC. Semin Thromb Hemost 1998; 24: 19-25.
  • Tahtacı N, Elmacıo
  • Niessen RWL, Lamping RJ, Jonsen PM, et. al. Antithrombin acts as a negative acute phase protein as established with studies on Hep G2 cells
  • and in baboons. Thromb Haemost 1997; 78:1088-1092.
  • Mammen EF, Balk R, Emerson T Jr, et. al. Therapeutic use of antithrombin concentrates in sepsis. Semin Thromb Hemost 1998; 24: 183-194.
  • Dickneite G. Antithrombin III in animal models of sepsis and organ failure. Semin Thromb Hemost 1998; 24: 61-69.
  • Warren BL, Eid A, Singer P, et. al. High dose antithrombin III in severe sepsis. A randomized controlled trial. JAMA 2001; 286: 1869-1878.
  • Olcay L, Gürgey A. Herediter trombotik hastalıklar. Katkı Pediatri Derg 1995; 6:887-907.
  • Casgriff JM, Bishop DT, Hersfold EJ, Skolnick MH, et. al. Hereditary antithrombin deficiency diagnosis and treatment. Medicine 1983; 62: 4.
  • Wilson C, Walker ID, Davidson JF. Mesenteric venous thrombosis and ATIII deficiency. J Clin Pathol 1987; 40: 906-908.
  • Lee MK. Cerebral Venous Thrombosis with ATIII deficiency. Aust NZ J Med 1991;21.
  • Levi M, Ten Cate H, Van der Poll T, Van Deventer SJH. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993; 270: 975-
  • -
  • Vervloet MG, Thijs LG, Hack CE. Derangement’s of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin Thromb
  • Hemostas 1998; 24: 33-44.
  • Mesters RM, Mannucci PM, Coppola R, Keller T, Ostermann H, Kienast J. Factor VIIa and antithrombin III activity during severe sepsis and septic
  • shock in neutropenic patients. Blood 1996; 88: 881-886.
  • Hellgren M, Javelin L, Hagnevik K, et. al. Antithrombin III concentrate as adjuvant in DIC treatment- a pilot study in 9 severely ill patients. Thromb
  • Res 1984; 36:459-466.
  • Blauhut B, Kramar H, Vinazzer H, et. al. Substitution of antithrombin III in shock and DIC: A randomised study. Thromb Res 1985; 29:81-89.
  • Montgomery RR, Scott JP. Hemorrhagic and thrombotic disease. Behrman Nelson Texbook Pediatrics 17th edition 2004; 1651-1656.
  • Nesheim ME. A simple rate low that describes the kinetics of the heparin catalysed reaction between antithrombin III and trombin. J Biol Chem
  • ; 23(14): 708.
  • Van der Poll T, van Deventer SJH. Cytokines and anticytokines in the pathogenesis of sepsis. Infect Dis Clin North Am 1999; 13: 413-426.
  • Bone RC. Modulators of coagulation. A critical appraisal of their role in sepsis. Arch Intern Med 1992; 152: 1381-1389.
  • Bone RC. Sepsis and coagulation. Ann Important Link. Chest 1992; 101 (3): 594-595.
  • Heyderman RS. Sepsis and intravascular thrombosis. Arch Dis Child 1993; 68: 621-625.
  • Fourrier F, Chopin C, Goudemand J, Hendryx S, Caron C, Rime A, et. al. Septic shock, multiple organ failure and disseminated intravascular
  • coagulation. Compared patterns of antithrombin III, protein C and protein S deficiencies. Chest 1992; 101: 816-823.
  • Mammen EF. The haematological manifestations of sepsis. J Antimicrob Chemother 1998; 41 (Suppl A): 17-24.
  • Levi M, ten Cate H, Disseminated intravascular coagulation. N Engl J Med 1999; 341: 586-592.
  • Bick RL. Disseminated intravascular coagulation: pathophysiological mechanisms and manifestations. Semin Thromb Hemostas 1998; 24: 3-18.
  • Blanco A, Guisasola JA, Solis P, Bachiller R, Gonzalez H. Fibronectin in meningococcal sepsis. Correlation with antithrombin III and protein C.
  • Acta Pediatr Scand 1990; 79: 73-76.
  • Fourrier F, Lestavel P, Chopin C, Marey A, Goudemand J, Rime A, et. al. Meningococcemia and purpura fulminans in adults: acute deficiencies of
  • protein C and protein S and early treatment with antithrombin III concentrates. Intensive Care Med 1990; 16: 121-124.
  • Sanchez MA, at al. Abnormalities in coagulation and fibrinolysis in septic shock with purpura. An Esp Pediatr 2002; 56(2): 99-103.
  • Dschietzig T, et.al. Stimulation of pulmonary big endothelin-1 and endothelin-1 by antithrombin III: a rationale for combined application of
  • antithrombin III and endothelin antagonist in sepsis-related acute respiratory distres syndrome? Crit Care Med. 2000 Jul; 28(7): 2445-9.
  • Uchiba M, Okajima K. Antithrombin III prevents LPS-induced vascular injury: Novel biological activity of ATIII. Thromb Haemostas 1997; 23: 583-
  • -
  • Sundar S, Mall RK, Dube B, Singh VP. Antithrombin III in liver disorders. J Assoc Physicians India. 1991; 39(7): 522-4.
  • Pettila V, Pentti J, Pettila M, Takkunen O, Jousela I. Predictive value of antithrombin III and serum C-reactive protein concentration in critically ill
  • patients with suspected sepsis. Crit Care Med 2002; 30(2): 271-5.
Toplam 57 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Konular Sağlık Kurumları Yönetimi
Bölüm Original Articles
Yazarlar

Bedir Ay Bu kişi benim

Murat Tutanç Bu kişi benim

Servet Yel Bu kişi benim

Metin Kaplan Bu kişi benim

Mehmet Boşnak Bu kişi benim

Emre Ayıntap Bu kişi benim

Yayımlanma Tarihi 3 Mart 2015
Gönderilme Tarihi 27 Şubat 2015
Yayımlandığı Sayı Yıl 2010 Cilt: 1 Sayı: 1

Kaynak Göster

Vancouver Ay B, Tutanç M, Yel S, Kaplan M, Boşnak M, Ayıntap E. YOĞUN BAKIMA YATAN HASTALARDA ATIII SEVİYESİ VE PROGNOSTİK DEĞERİ. mkutfd. 2015;1(1):1-5.